Evotec AG and the Helmholtz Centre for Infection Research (“HZI”) have entered a collaboration with the goal to address a major global health threat by developing novel antibiotics that overcome drug-resistant bacterial pathogens.    Research activities will initially be focused on the optimization of cystobactamids, a family of natural antibacterial products with innovative chemical scaffolds that are active against the most dangerous Gram-negative pathogens on the WHO prior...